Location · Durham, NC
Clinical trials in Durham, NC
245 recruiting studies have a site in Durham, and 95 of them accept healthy volunteers.
245 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
Merck Sharp & Dohme LLC
- Location
- Durham, NC + 23 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell…
Incyte Corporation
- Location
- Durham, NC + 29 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Diagnosing Epilepsy To EffeCT Change
Epiminder America, Inc.
- Location
- Durham, NC + 21 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
Regeneron Pharmaceuticals
- Location
- Durham, NC + 35 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis
Priovant Therapeutics, Inc.
- Location
- Durham, NC + 34 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Novo Nordisk A/S
- Location
- Durham, NC + 58 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Strategy for Improving Stroke Treatment Response
Translational Sciences, Inc.
- Location
- Durham, NC + 37 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Annexon, Inc.
- Location
- Durham, NC + 19 other US sites
- Eligibility basics
- Ages 8–85
- RecruitingPhase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Sanofi
- Location
- Durham, NC + 72 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 3
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
SymBio Pharmaceuticals
- Location
- Durham, NC + 24 other US sites
- Eligibility basics
- Ages 2 mo+
- RecruitingPhase 3
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Vor Biopharma
- Location
- Durham, NC + 46 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2/Phase 3
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
Cabaletta Bio
- Location
- Durham, NC + 9 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Pridopidine Phase 3 Study in Huntington's Disease
Prilenia
- Location
- Durham, NC + 8 other US sites
- Eligibility basics
- Ages 23–65
- RecruitingPhase 2/Phase 3
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Cabaletta Bio
- Location
- Durham, NC + 29 other US sites
- Eligibility basics
- Ages 6–75
- RecruitingPhase 2
A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)
Pfizer
- Location
- Durham, NC + 10 other US sites
- Eligibility basics
- Up to age 10 mo
- RecruitingPhase 2
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette);
Genentech, Inc.
- Location
- Durham, NC + 14 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
Pfizer
- Location
- Durham, NC + 68 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Gaucher Disease Gene Therapy Trial With FLT201
Spur Therapeutics
- Location
- Durham, NC + 12 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
AstraZeneca
- Location
- Durham, NC + 93 other US sites
- Eligibility basics
- Ages 18–130
- RecruitingPhase 3
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Cytokinetics
- Location
- Durham, NC + 80 other US sites
- Eligibility basics
- Ages 18–85
- Recruiting
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
Reprieve Cardiovascular, Inc
- Location
- Durham, NC + 33 other US sites
- Eligibility basics
- Ages 22+
- RecruitingPhase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Insmed Incorporated
- Location
- Durham, NC + 12 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Merck Sharp & Dohme LLC
- Location
- Durham, NC + 20 other US sites
- Eligibility basics
- Up to age 17
- RecruitingPhase 1/Phase 2
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)
AskBio Inc
- Location
- Durham, NC + 4 other US sites
- Eligibility basics
- Ages 18–65